Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. uri icon

authors

  • Friedlander, Michael
  • Banerjee, Susana
  • Oza, Amit
  • González-Martín, Antonio
  • Aghajanian, Carol
  • Bradley, William H
  • Liu, Joyce
  • Mathews, Cara
  • Selle, Frédéric
  • Lortholary, Alain
  • Lowe, Elizabeth S
  • Moore, Kathleen N
  • Hettle, Robert
  • Flood, Emuella
  • Parkhomenko, Elena
  • DiSilvestro, Paul
  • Colombo, Nicoletta
  • Scambia, Giovanni
  • Kim, Byoung-Gie
  • Oaknin, Ana
  • Lisyanskaya, Alla
  • Sonke, Gabe S
  • Gourley, Charlie

publication date

  • January 1, 2021